基本信息

姓名：刘婷婷

职称：研究员

电子邮箱：cpultt126@126.com 

教育经历

2017/09- 2021/07, 中国药科大学，生药学，博士；

2014/09 - 2017/07, 中国药科大学，天然药物化学，硕士；

2010/09 - 2014/07, 中国药科大学，中药学，学士；

工作经历

2024/09-至今，获内蒙古大学“骏马计划”人才引进，任内蒙古大学生物医学研究院研究员；

2021/08-2024/08，北京大学，博士后；

研究方向

主要从事中蒙药活性成分的作用靶点鉴定与药理机制研究，综合运用化学生物学、结构生物学等，构建系列靶点高效发现技术体系，精准揭示中蒙药药效成分直接作用靶点与分子机制，挖掘疾病治疗新靶点及新的先导药物分子。

科研项目

(1) 国家自然科学基金委员会, 青年科学基金项目（C类）[原青年科学基金项目], 82304785, 基于乳腺癌类器官的华蟾酥毒基“原位”靶点鉴定及作用机制研究, 2024-01-01 至 2026-12-31, 30万元, 在研, 主持；

(2) 国家自然科学基金委员会, 面上项目, 82474060, 龙血通络胶囊靶向神经血管单元抗缺血性脑卒中药效成分群直接靶点鉴定与分子机制, 2025-01-01 至 2028-12-31, 49万元, 在研, 参与；

(3) 国家自然科学基金委员会, 地区科学基金项目, 82260763, 基于代谢组学技术的蒙药嘎日迪-13靶向神经血管单元治疗“白脉病”质控新模式研究, 2023-01-01 至 2026-12-31, 33万元, 在研, 参与；

代表性论文

代表性论文（*共同一作，#共同通讯）：

(1) Liu TT*, Yang H, Zhuo FF, Yang Z, Zhao MM, Guo Q, Liu Y, Liu D, Zeng KW^#, Tu PF^#. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy. eBioMedicine, 2022, 86: 104353.

(2) Zhou XQ*, Zhao SY*, Liu TT*, Yao L, Zhao MM, Ye X, Zhang X, Guo Q, Tu PF, Zeng KW^#. Schisandrol A protects AGEs-induced neuronal cells death by allosterically targeting ATP6V0d1 subunit of V-ATPase. Acta Pharmaceutica Sinica B, 2022, 12(10): 3843-3860.

(3) Liu TT*, Guo Q, Zheng SZ, Liu Y, Yang H, Zhao MM, Yao L, Zeng KW^#, Tu PF^#. Cephalotaxine inhibits the survival of leukemia cells by activating mitochondrial apoptosis pathway and inhibiting autophagy flow. Molecules, 2021, 26(10): 2996

(4) Hu SN*, Liu TT*, Wu YL, Yang WQ, Hu SB, Sun ZX, Li PY^#, Du SY^#. Panax notoginseng saponins suppress lipopolysaccharide-induced barrier disruption and monocyte adhesion on bEnd.3 cells via the opposite modulation of Nrf2 antioxidant and NF-κB inflammatory pathways. Phytotherapy Research, 2019, 33(12): 3163-3176.

(5) Liu TT*, Yao RL, Zhao YC, Xu S, Huang CL, Luo J^#, Kong LY^#. Cloning, functional characterization and site-directed mutagenesis of 4-coumarate: coenzyme A ligase (4CL) involved in coumarin biosynthesis in Peucedanum praeruptorum Dunn. Frontiers in Plant Science, 2017, 8: 4.

(6) Zeng KW*, Wang JK*, Wang LC, Guo Q, Liu TT, Wang FJ, Feng N, Zhang XW, Liao LX, Zhao MM, Liu D, Jiang Y, Tu PF*. Small molecule induces mitochondrial fusion for neuroprotection via targeting CK2 without affecting its conventional kinase activity. Signal Transduction and Targeted Therapy, 2021, 6(1): 71.

(7) Zhao MM*, Ren TT*, Wang JK, Yao L, Liu TT, Zhang JC, Liu Y, Yuan L, Liu D, Xu JH, Tu PF, Tang XD*, Zeng KW*. Endoplasmic reticulum membrane remodeling by targeting reticulon-4 induces pyroptosis to facilitate antitumor immune. Protein Cell, 2025, 16(2): 121-135.

(8) Yang Z*, Zhang XW, Zhuo FF, Liu TT, Luo QW, Zheng YZ, Li L, Yang H, Zhang YC, Wang YH, Liu D, Tu PF, Zeng KW*. Allosteric activation of transglutaminase 2 via inducing an "Open" conformation for osteoblast differentiation. Adv Sci (Weinh), 2023, 10(18): e2206533.

(9) Luo QW*, Yao L, Li L, Yang Z, Zhao MM, Zheng YZ, Zhuo FF, Liu TT, Zhang XW, Liu D, Tu PF, Zeng KW*. Inherent capability of self-assembling nanostructures in specific proteasome activation for cancer cell pyroptosis. Small, 2023, 19(9): e2205531.

(10) Yao L*, Zhao MM, Luo QW, Zhang YC, Liu TT, Yang Z, Liao M, Tu P, Zeng KW*. Carbon quantum dots-based nanozyme from coffee induces cancer cell ferroptosis to activate antitumor immunity. ACS Nano, 2022, 16(6): 9228-9239.

(11) Guo Q*, Zhang YC, Wang W, Wang YQ, Liu Y, Yang Z, Zhao MM, Feng N, Wang YH, Zhang XW, Yang H, Liu TT, Shi LY, Shi XM, Liu D, Tu PF^#, Zeng KW^#. Deoxyhypusine hydroxylase as a novel pharmacological target for ischemic stroke via inducing a unique post-translational hypusination modification. Pharmacological Research, 2022, 176: 106046.

(12) Liu Y*, Guo Q, Yang H, Zhang XW, Feng N, Wang JK, Liu TT, Zeng KW^#, Tu PF^#. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment. ACS Central Science, 2022, 8(8): 1102-1115.